Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Colorcon
Farmers Insurance
UBS
Baxter
Cipla
Citi
McKesson
Moodys
AstraZeneca

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,906,519

« Back to Dashboard

Which drugs does patent 7,906,519 protect, and when does it expire?

Patent 7,906,519 protects COLCRYS and is included in one NDA.
Summary for Patent: 7,906,519
Title:Methods for concomitant administration of colchicine and a second active agent
Abstract:Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
Inventor(s): Davis; Matthew W. (Erwinna, PA)
Assignee: AR Holding Company, Inc. (Wilmington, DE)
Application Number:12/858,754
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,906,519

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms Usa COLCRYS colchicine TABLET;ORAL 022352-001 Jul 29, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,906,519

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,440,721 Methods for concomitant administration of colchicine and a second active agent ➤ Subscribe
7,820,681 Methods for concomitant administration of colchicine and a second active agent ➤ Subscribe
7,915,269 Methods for concomitant administration of colchicine and a second active agent ➤ Subscribe
8,440,722 Methods for concomitant administration of colchicine and a second active agent ➤ Subscribe
8,093,297 Methods for concomitant administration of colchicine and a second active agent ➤ Subscribe
7,964,648 Methods for concomitant administration of colchicine and a second active agent ➤ Subscribe
8,445,541 Methods for concomitant administration of colchicine and a second active agent ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
US Department of Justice
Moodys
UBS
Farmers Insurance
Covington
Merck
Teva
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot